发明申请
- 专利标题: TUMOR-SPECIFIC DELIVERY OF THERAPEUTIC AGENTS VIA LIPOSOMASE
- 专利标题(中): 通过脂质体的肿瘤特异性递送治疗药物
-
申请号: US12304178申请日: 2007-06-19
-
公开(公告)号: US20110250258A1公开(公告)日: 2011-10-13
- 发明人: Ian Cheong , Shibin Zhou , Kenneth W. Kinzler , Bert Vogelstein
- 申请人: Ian Cheong , Shibin Zhou , Kenneth W. Kinzler , Bert Vogelstein
- 申请人地址: US MD BALTIMORE
- 专利权人: JOHNS HOPKINS UNIVERSITY
- 当前专利权人: JOHNS HOPKINS UNIVERSITY
- 当前专利权人地址: US MD BALTIMORE
- 国际申请: PCT/US07/14274 WO 20070619
- 主分类号: A61K9/127
- IPC分类号: A61K9/127 ; C12N15/85 ; C12N15/86 ; A61P35/00 ; A61K39/395 ; C12N9/96 ; C07H21/04 ; C12N9/20 ; A61K35/74
摘要:
Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.
公开/授权文献
信息查询